Lonza Group AG, of Basel, Switzerland, said it will acquire Capsugel SA, a firm specializing in oral dosage delivery technology, for $5.5 billion, including refinancing of existing Capsugel debt of about $2 billion. Read More
A proposed settlement has been reached in a lawsuit regarding the price that people in 48 states and District of Columbia paid for sleep disorder drug Provigil (modafinil) and generic versions of Provigil. Read More
Oncorus Inc., of Cambridge, Mass., said Astellas Venture Management LLC provided series A financing support to the company, increasing its series A proceeds to $61 million. Read More
Though it has become clear that tumor cells are found in the circulation early on in cancer development, metastasis is still thought of as a late event, on the theory that only cells that have accumulated multiple mutations would be capable of establishing outposts. Read More
Vtv Therapeutics Inc. reported that its oral GLP-1 receptor agonist, TTP273, helped type 2 diabetics on stable doses of metformin achieve mean placebo-subtracted HbA1c differences of up to -0.86 percent during a phase II study, giving it confidence to continue advancing the program, one of two diabetes-focused efforts at the company. Read More
Taking aim at human papillomavirus (HPV)16-induced cervical lesions in a phase I/IIa study with its therapeutic cancer vaccine, Norway-based Vaccibody AS added NOK220 million (US$25 million) to the coffers in a private placement, selling 880,000 shares at NOK250 each. Read More
Noxxon Pharma NV, of Berlin, said it inked a collaboration agreement with Merck & Co. Inc., of Kenilworth, N.J., to conduct a phase I/II trial testing Noxxon's anti-CXCL12 agent, NOX-A12, in combination with Merck's anti-PD-1 antibody Keytruda (pembrolizumab) in patients with metastatic solid tumors that do not usually respond to checkpoint inhibitor monotherapy. Read More
